相关实验视频

Updated: Jun 24, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

KRAS作为转移性非小细胞肺癌的预后和预测标记:系统性审查

Sheereen Fatima¹, Nirav Pansuriya², Alisha Lakhani^3,4

¹Cancer Center, Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, IND.

|June 11, 2024

概括

KRAS突变会影响转移性非小细胞肺癌 (NSCLC) 的结果. 野生型KRAS患者对化疗反应更好,而突变型KRAS患者受益于免疫检查点抑制剂,指导个性化NSCLC治疗.

科学领域:

在瘤学瘤学.
遗传学遗传学是一个
临床试验临床试验

背景情况:

转移性非小细胞肺癌 (NSCLC) 提出了重大挑战.
在NSCLC中,KRAS突变越来越被认为是关键突变.
针对性疗法需要了解KRAS突变的作用.

研究的目的:

系统地审查KRAS突变在转移性NSCLC中的预后和预测作用.
根据KRAS突变状态分析治疗反应.
为NSCLC患者提供个性化治疗策略的信息.

主要方法:

对MEDLINE,Embase,Scopus和Cochrane注册表进行系统审查 (2023年6月).
包括2013-2022年期间的12项研究 (2项RCT,10项观察性),涉及2845名患者.
提取关于生存和治疗反应的数据;使用NOS和修改后的Jadad分数进行质量评估.

主要成果:

KRAS突变,特别是G12C,在转移性NSCLC中显著影响治疗反应.
野生型KRAS患者对基化疗反应更好.
有KRAS突变的患者在使用免疫检查点抑制剂 (ICI) 时表现出良好的结果.

结论:

KRAS突变是转移性NSCLC的重要预后指标.
区分KRAS野生类型和突变状态指导化疗或ICI的选择.
对KRAS抑制剂和向疗法的进一步研究是个性化的NSCLC管理所需的.

关键词:

克拉斯基突变克拉斯基突变肺癌是一种肺癌.转移性非小细胞肺癌癌.预测性标记物预测性标记物预后标志物预后标志物

更多相关视频

Detection of Lung Tumor Progression in Mice by Ultrasound Imaging

Detection of Lung Tumor Progression in Mice by Ultrasound Imaging

Published on: February 27, 2020

A 3D Organotypic Melanoma Spheroid Skin Model

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

相关概念视频

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...